



PROMOVAX

Promote Vaccinations among Migrant Populations in Europe

newsletter

ISSUE 3, April 2012

www.promovax.eu

PROMOVAX is a 3-year EU-funded project (2010-2013) aiming to promote immunizations among migrant populations in Europe.

U ovom broju:

1. Uvriježene prakse procjepljivanja migranata utvrđene su i vrednovane u okviru 5. projektnog zadatka PROMOVAX projekta. Popis najboljih među njima sada je dostupan na mrežnoj stranici projekta.

2. Temeljem utvrđenih najboljih praksi procjepljivanja migranata te temeljem procjene potreba za procjepljivanjem ove populacije učinjene u okviru 4. projektnog zadatka nazvanog „Mapiranje podrijetla migranata koji dosegavaju na područje EU-e i pristupačnost cjepiva i cjepnih stanica“, načinjene su preporuke za procjepljivanje migranata. Kratki pregled dokumenta u kome su sadržane uključen je u ovaj broj „Promovax novosti“.

3. Naposlijetu, kao dio naših nastojanja da prezentiramo relevantne projekte i inicijative, možete saznati više o Mreži kliničara koji skrbe za migrante (u izvorniku: *Migrant Clinicians Network*).

4. Pregled sadržaja četvrtoga sastanka partnera – sudionika projekta.

1. Procjepljivanje migranata – najbolje prakse u EU-i:

Utvrđili smo da postoje ukupno **33 programa procjepljivanja koje se može vrednovati i rangirati sukladno instrumentu nazvanom "Instrument za vrednovanje najbolje prakse procjepljivanja migranata"**, koji smo zajednički osmisili i pripremili.

Popis najboljih praksi procjepljivanja migranata sada je dostupan na mrežnoj stranici projekta <http://www.promovax.eu/index.php/promovax/vaccination/vac3>

2. Preporuke glede procjepljivanja migranata:

Temeljem velikoga broja podataka prikupljenih u državama članicama EU-e te temeljem analize trenutno postojećih praksi procjepljivanja migranata, **PROMOVAX konzorcij** preporučuje uvođenje i/ili prilagodbu državne i/ili lokalne prakse procjepljivanja migranata koja udovoljava sljedećim kriterijima:

1. Učinkovit program procjepljivanja migranata mora biti kontinuiran i održiv te povesti računa o dostupnosti ciljnoj skupini (npr. klinike u kojima se vrši procjepljivanje s fleksibilnim radnim vremenom, koje rade u popodnevni ili večernjim satima).
2. **Jezična barijera** prijeći korištenje zdravstvenih usluga. Isto se može razrješiti angažiranjem prevoditelja koji trebaju raditi bez naknade. Uz to, kad god je moguće, od velike je pomoći na takvim lokacijama angažirati zdravstveno osoblje i liječnike koji govore jezike ciljne manjine, napose ako je riječ o područjima koje naseljava stanovništvo koje gotovo da i ne govori službenim jezikom zemlje u kojoj je nastanjeno.
3. Programi procjepljivanja moraju uzeti u obzir **kulturološke razlike** te nastojati premostiti ovu barijeru angažiranjem posrednika koji poznaje kulturu ciljne manjine. Njegova uloga seže daleko iznad uloge puškog prevoditelja. U državama u kojima se programi procjepljivanja migranata uspješno provode, ovakvi posrednici obučeni su da djeluju kao edukatori, promicatelji zdravlja i osobe koje će obitelji migranata uputiti u ustroj zdravstvenoga sustava i njegovo funkciranje te im savjetovati kome da se obrate.
4. **Cijena** može biti značajna zapreka učinkovitom provođenju programa procjepljivanja. Kako bi se migrantima omogućilo da se procijepi u što većem broju, cjepiva za njih valja osigurati besplatno. U okviru uspješnih inicijativa procjepljivanja osigurana su novčana sredstva za brojne resurse.
5. Dobro osmišljeni program mora osigurati procjepljivanje u okviru kojega će se povesti računa o **individualnim karakteristikama** svakoga pojedinoga migranta.
6. Uspješni programi procjepljivanja **prate se i vrednuju** na središnjoj i na lokalnim razinama, pri čemu se vodi računa kako o kvaliteti, tako i o ishodima ovih aktivnosti (pokazatelji ishoda koji ukazuju i na kvantitativne i na kvalitativne aspekte).
7. **Prikupljanje podataka** i istraživanja koja se tiču zdravlja migranata i njihova socioekonomskoga statusa, od ključnoga su značaja za dobivanje podrobnjih i realnijih povratnih informacija o situaciji koja vlada u ciljnoj skupini.
8. **Uporaba registra i knjižice cijepljenja** preporučuje se stoga što se time olakšava daljnje vrednovanje postignutih rezultata te stoga što su isti od ključnoga značaja za stvaranje dosljedne baze podataka o zdravstvenom stanju migranata.



PROMOVAX

3. Mreža kliničara koji skrbe za migrante (*Migrant Clinicians Network*) – prikaz modela najbolje prakse u području procjepljivanja migranata

Mreža kliničara koji skrbe za migrante (MCN; od eng. *Migrant Clinicians Network*) obuhvaća preko 10 000 zdravstvenih radnika svih profila koji prakticiraju u SAD-u i promiču pravičnu zdravstvenu zaštitu siromašnih migranata. Pristupačnost cjepnih stanica i cjepiva prilagođena migrantima, zdravstvena sigurnost i izobrazba migranata te stalno upotpunjavanje aktivnosti, predstavljaju ciljeve ovoga programa već zadnjih dvadeset godina, a ta nastojanja podupire nekoliko inicijativa širokoga obuhvata. Središnji uredi MCN-a nalaze se u Austinu u saveznoj državi Texas, pri čemu je ostvarena suradnja sa 700 zdravstvenih klinika koje se financiraju iz saveznoga proračuna te s nizom drugih zdravstvenih ustanova i zavoda, organizacija koje djeluju na razini lokalne zajednice i sveučilištima.

Pri provođenju zadnjega, nedavno završenoga programa procjepljivanja usmjerenoga na povećanje stope procijepjenosti migranata kako na nacionalnoj, tako i na lokalnoj razini, MCN je ostvario partnerstvo s Centrima za kontrolu bolesti (*Centers for Disease Control*). Zdravstveni radnici koji prakticiraju u lokalnoj zajednici i rade s populacijom migranata hispanskog podrijetla, nazvani promicateljima (*promotoras*), bili su stacionirani u klinikama te meksičkim konzulatima. Oni su ovu populaciju na kulturološki primjeren način educirali o značaju cijepljenja i organizirali kampanje procjepljivanja, odnosno spomenutim migrantima osiguravali dostupnost lokalnih klinika. Foto-novele čije praćenje ne iziskuje visok stupanj izobrazbe i kulturološki primjeren osmišljeni DVD-ovi čiji su sadržaj činili materijali po kojima se mogu sprječiti procjepljivanjem i obilježjima procjepljivanja, pripremljeni su i rasplaćeni diljem države.

Resursi osigurani kliničarima uključuju pomoći pri mjerjenju stopa procijepjenosti lokalnih migrantskih zajednica, izobrazbu o posebnim potrebama za procjepljivanjem koje imaju putnici i useljenici, promicanje ubrzanog programa procjepljivanja namijenjenoga migrantima i osiguranje doživotne skrbi i praćenja stanja procijepjenosti, osmišljenih na način primjeren niskoj obrazovnoj razini migrantske populacije i usredotočenih na potrebe bolesnika. Novija nastojanja uključuju povezivanje kampanja procjepljivanja od gripe s provođenjem tzv. "strategije procjepljivanja u povojima" (u izvorniku: "cocooning" strategy); strategija procjepljivanja dojenčadi, članova njihove obitelji i svih osoba koje s njima redovito dolaze u doticaj, op.prev.) na TdaP (tetanus, difterija i acelularni pertusis), kako bi se sprječilo pojavu hripcavca u populacijama migranata. Ova nastojanja reakcija su na podatke o nejednakostima u pogledu zdravstvene skrbi, koji pokazuju da su vremenski useljenici hispanskoga podrijetla oni koje se najprije cijepi protiv gripe, ali i reakcija na epidemiju hripcavca koja je 2010. godine izbila u Kaliforniji i odnijela životе desetero hispanske dojenčadi, uz još jednu smrt dojenčeta-migranta zabilježenu u saveznoj državi Washington. U aktivnosti koje se već tradicionalno provode u određenim medicinskim centrima, aktivnosti novijega datuma poglavito će se odvijati u meksičkim konzulatima diljem SAD-a. U tradicionalne metode rada MCN-a spada i rad na terenu te osiguranje cijepiva na radilištima i u područjima koja naseljavaju migranti.

Za podrobnije informacije i pristup našim besplatnim pisanim materijalima o procjepljivanju, molimo posjetite mrežnu stranicu www.migrantclinician.com

i kontaktirajte dr. Jennie McLaurin, MD, MPH, na e-mail adresu:

jmcclaurin@migrantclinician.com.

4. Četvrti sastanak partnera – sudionika Promovax projekta

Četvrti sastanak partnera – sudionika PROMOVAX projekta održat će se u Ateni u Grčkoj, a na njemu će sudjelovati svi pridruženi partneri te pozvani suradni partneri i stručnjaci. Konkretnije rečeno, na sastanak će biti pozvani stručnjaci iz Regionalnoga ureda SZO-e za Evropu, Međunarodne organizacije za migracije (IOM; od eng. International Organisation for Migration) i Europskoga centra za prevenciju i kontrolu bolesti (ECDC; od eng. European Centre for Disease Prevention and Control), kao i stručnjaci njemačkoga Etno-medicinskoga centra i američke Mreže kliničara koji skrbe za migrante, specijalizirani za osmišljavanje i razvoj metodoloških instrumenata koji se koriste u medicinskim istraživanjima, kako bi dali svoj obol i iznijeli svoje sugestije.

Glavni cilj ovog sastanka jest priprema edukacijskoga materijala namijenjenoga zdravstvenim radnicima i migrantima. Preliminarni program sastanka molimo proučite na mrežnoj stranici (www.promovax.eu)

SASTANCI ZAKAZANI U OKVIRU PROMOVAX PROJEKTA

05.03.2012

4. sastanak partnera – sudionika projekta

4. sastanak partnera – sudionika PROMOVAX projekta, Atena, Grčka

EU radionica će se održati u Bruxellesu početkom srpnja 2012. godine

NOVOSTI U OKVIRU PROMOVAX PROJEKTA

2. nacionalna konferencija Forum za javno zdravstvo i socijalnu medicinu, Larisa, Grčka, 25-27.11.2011

PROMOVAX projekt usmeno je prezentirala dr. Eleni Patrozou

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.

The PROMOVAX Project has received funding from the European Union / DG Health and Consumer Protection. The European Commission and the Executive Agency are not responsible for any use that may be made of the information contained on this website.